RECRUITING Not applicable ClinicalTrials.gov

Video-oculography and Parkinson's Disease

Sponsor: Association de Recherche Bibliographique pour les Neurosciences • ClinicalTrials.gov ID: NCT04731246

Registry updated: 2026-10-13

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015): * the evolution of oculomotricity markers over time. * the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years. * the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography. * the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.

Interventions

Video-oculography / Neuropsychological evaluations (Other)
Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET/CT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.

Eligibility criteria

\*Inclusion Criteria: 1. Male or Female; 2. Clinically defined idiopathic Parkinson's Disease (PD); 3. Brain MRI performed in routine care in the 12 months preceding inclusion; 4. Cerebral DaTSCAN or cerebral PET with F-DOPA, performed as routine care before inclusion (no time limit), confirming presynaptic dopaminergic denervation; 5. Hoehn \& Yahr score: 1 to 3; 6. Normal clinical examination of oculomotricity (slight impairment of smooth pursuit accepted); 7. Neuro-cognitive disorders: absent or minor (according to DSM5); 8. Sufficient written and oral expression in French; 9. Covered by a health insurance system; 10. Written informed consent signed by the patient; 11. Presence of a caregiver. \* Exclusion Criteria: 12. Psychiatric comorbidity (except anxiety or mild to moderate depression); 13. Neurological comorbidity, if significant; 14. Brain MRI showing: 1. significant cerebrovascular pathology (Fazekas I admitted), 2. another brain disease, including stroke. 15. Major cognitive impairment; 16. Absolute exclusion criteria and "Red flags" of the 2015 criteria orienting towards another degenerative pathology of the extrapyramidal system: * Cerebellar syndrome * Vertical oculomotricity disorders on clinical examination * Motor symptoms restricted to the lower limbs * Bilateral and perfectly symmetrical parkinsonism * Early dystonia * Clinical profile suggestive of behavioral variant frontotemporal dementia (bvFTD) * Progressive aphasia or apraxia * Moderate or severe postural instability and / or early falls * Early bulbar dysfunction (dysarthria, swallowing disorders) * Ventilatory dysfunction (inspiration) * Severe dysautonomia * DOPA-resistance * Neuroleptic treatment or related 17. Normal MIBG myocardial scintigraphy (if performed).

Conditions

Parkinson Disease, Idiopathic

Locations

Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital — Monaco, Monaco

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment